Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design

Stroke

Volumn 33, Issue 6, 2002, Pages 1545-1550

  Muir, Keith W ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Controlled clinical trials; Neuroprotection

Indexed keywords

NEUROPROTECTIVE AGENT;

ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL; DISEASE CLASSIFICATION; HUMAN; NEUROPROTECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RELIABILITY; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL MODEL; STROKE;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; MODELS, STATISTICAL; NEUROPROTECTIVE AGENTS; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 0036281510     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000018684.86293.AB     Document Type: Article

References (27)

1. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
2. Have randomized controlled trials of neuroprorective drugs been underpowered? An illustration of three statistical principles
3. Considerations in the design of clinical trials of neuroprotective therapy in acute stroke
4. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischemia
5. Glutamate is a marker for cerebral ischemia in cortical but not deep infarcts
6. Tissue at risk of infarction rescued by early reperfusion: A positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke
7. No evidence of hypoxic tissue on 18F-fluoromisonidazole PET after intracerebral hemorrhage
8. Clomethiazole Acute Stroke Study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
9. Impact on stroke subtype diagnosis of early diffusion-weighted magnetic resonance imaging and magnetic resonance angiography
10. Identification of lacunar infarcts before thrombolysis in the ECASS I study
11. Absent middle cerebral artery flow predicts the presence and evolution of the ischemic penumbra
12. Classification and natural history of clinically identifiable subtypes of cerebral infarction
13. Tissue plasminogen activator for acute ischemic stroke
14. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II study: A randomized controlled trial: Prolyse in acute cerebral thromboembolism
15. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial: Stroke treatment with ancrod trial
16. Limitations of clinical diagnosis in acute stroke
17. Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI
18. Role of CT angiography in patient selection for thrombolytic therapy in acute hemispheric stroke
19. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI
20. Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI
21. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: A randomised controlled trial: GAIN International Investigators
22. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis: North American Symptomatic Carotid Endarterectomy Trial Collaborators
23. Choice of endpoints in antiplatelet trials: Which outcomes are most relevant to stroke patients?
24. Neuroprotection for acute stroke: Making clinical trials work
25. Which targets are relevant for therapy of acute ischemic stroke?
26. Is there an apparent diffusion coefficient threshold in predicting tissue viability in hyperacute stroke?
27. Effect of citicolineon ischemic lesions as measured by diffusion-weighted magnetic resnance imaging: Citicoline 010 Investigators